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For centuries, macrofungi have been used as food and medicine in different parts of the world. This is mainly attributed to their
nutritional value as a potential source of carbohydrates, proteins, amino acids, and minerals. In addition, they also include many
bioactive metabolites which make mushrooms and truffles common components in folk medicine, especially in Africa, the Middle
East, China, and Japan. The reported medicinal effects of mushrooms include anti-inflammatory effects, with anti-inflammatory
compounds ofmushrooms comprising a highly diversified group in terms of their chemical structure.They include polysaccharides,
terpenoids, phenolic compounds, andmany other lowmolecularweightmolecules.The aims of this review are to report the different
types of bioactive metabolites and their relevant producers, as well as the different mechanisms of action of mushroom compounds
as potent anti-inflammatory agents.
1. Introduction
In the human body, inflammation is considered to be part of
the complex biological response to remove injury or harmful
stimuli such as pathogens, damaged cells, or irritation. This
response leads tomanyphysical symptoms such as fever, pain,
and swelling, as a result of many associated changes such
as vasodilation, increased vascular permeability, and plasma
extravasation. Nowadays, the nonsteroidal anti-inflamma-
tory drugs (NSAIDs) are usually the most commonly admin-
istrated drug to reduce inflammation in the body.Many stud-
ies, however, have shown that the long-term administration
of NSAIDs has the potential for significant side effects on the
gastrointestinal tract (GIT).These include numerous harmful
effects such as mucosal lesions, bleeding, peptic ulcers, and
intestinal perforation [1, 2]. Other studies, meanwhile, have
suggested that the side effects of NSAIDs are not limited
only to GIT but extend to other serious complications such
as acute renal failure, nephrotic syndrome, hypertension,
and cardiovascular toxicity [3–5]. Recently, therefore, much
effort has been devoted towards the discovery of alternative
anti-inflammatory compounds of plant origin as potential
natural and safe medicines without the harmful side effects
of NSAIDs [6–11]. While a variety of plants have traditionally
been used in human medicine, mushrooms also have a long
history as important components of folk medicine and have
been widely used in the form of aqueous extracts in many
African, Middle Eastern, European, Asian, and native Aus-
tralian cultures for the treatment of different diseases as well
as a preventive medicine [12–16].
Mushrooms are a very large and diversified group of
macrofungi belonging to Basidiomycetes and Ascomycetes;
with a cell cycle including the formation of sexual spores.
The fungal spores for these two groups are located in a
special structure called the basidium (for Basidiomycetes)
or the ascus (for Ascomycetes), and such mushrooms can
grow either above the earth (epigeous macrofungi), giving
mainly umbrella like structures which include basidiospores,
or at depths of 10–20 cm below the soil surface (hypogeous
macrofungi or truffles). The latter of these belong mainly to
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Ascomycetes and usually grow in a symbiotic relationship
with a host plant as ectomycorrhizal mushrooms (EMM).
Both types of mushrooms have considerable nutritional
value, since they are rich sources of carbohydrates, proteins,
free amino acids, and vitamins, as well as different essential
minerals and trace elements [17, 18]. They are also rich in
many bioactive metabolites of high medicinal value such as
lectins, polysaccharides, phenolics and polyphenolics, terpe-
noids, ergosterols, and volatile organic compounds [19–21].
Mushroom extracts have therefore been used medicinally in
immunomodulator [22–25], antitumor/anticancer [26–30],
antibacterial and antiviral [31–33], antioxidant [34–37], and
antihypoglycaemic [38–40] applications and as activemedici-
nes in the prevention of cardiovascular diseases through their
action as antiatherosclerotic agents [41]. In addition, many
compounds of highly diversified chemical structures with
anti-inflammatory activities have been isolated and purified
from different types of mushrooms. It has been reported, for
example, that water, methanolic, ethanolic, and ethyl acetate
extracts of different epigeous and hypogeous mushrooms
showed significant decreases in the activities of inflamma-
tory mediators such as nitric oxide (NO), cytokines, and
prostaglandins, thus inhibiting some macrophage functions
and reducing cell inflammations.
2. Inflammation and Cell Molecular Signaling
Inflammation is a complex set of interactions among soluble
factors and cells that can arise in any tissue in response to
trauma, infections, or postischaemic, toxic, or autoimmune
injury [42]. In normal cases, the body’s response to inflam-
mation is self-limiting through the downregulation of proin-
flammatory protein expression, the increased expression of
anti-inflammatory proteins, and a reversal in the vascular
changes that facilitated the initial immune cell recruitment
process [43]. The processes leading to inflammation are usu-
ally linked to the activities of the cells involved in the restora-
tion of tissue structure and function. When cells are exposed
to immune stimulants, the proinflammatory cells, such as
macrophages, monocytes, or other host cells, start to produce
many molecular mediators which initiate the inflammation
process. Of the various inflammatory biomarkers that are
produced, themostwell-known are interleukins (IL-1𝛽), IL-6;
IL-8; tumour necrosis factor (TNF-𝛼); nuclear factor-𝜅B (NF-
𝜅B), intercellular adhesion molecule-1 (ICAM-1), inducible
type cyclooxygenase- (COX-) 2, prostaglandin E2 (PGE2); 5-
lipooxygenase (5-LOX); and inducible nitric oxide synthase
(iNOS), which leads to the production of reactive nitrogen
species such as nitric oxide (NO). Overproduction of these
inflammatory mediators leads to different kinds of cell
damage. In addition, prolonged inflammation causes many
inflammatory diseases such as juvenile idiopathic arthritis
(JIA), inflammatory bowel disease (IBD), multiple sclerosis,
rheumatoid arthritis, gastritis, bronchitis, and atherosclero-
sis [44]. A strong link has also been established between
long-term inflammation and the development of cancers
[45]. In some types of cancer, inflammation occurs before
malignant changes in the cells. In other types, oncogenic
change induces an inflammatory microenvironment that
promotes tumour development [46]. As a result, increased
attention is now being focused on efforts to discover bioactive
compounds which have the ability to suppress the produc-
tion of inflammatory mediators. In this context, mushroom
metabolites have been employed as potent, natural, and
safe anti-inflammatory compounds based on their ability to
reduce the production of inflammatory mediators through
downregulation of the gene expression of different types of
these inflammatory mediators.
3. Anti-Inflammatory Compounds of
Mushrooms and Modes of Action
Mushrooms are widely used for their high nutritional value
as a functional food. Additionally, they have been highly
appreciated for their medicinal and therapeutic applications
[47, 48]. Edible mushrooms produce a vast diversity of bioac-
tive compounds such as polysaccharides, proteoglucans,
terpenoids, phenolic compounds, steroids, and lectins.These
compounds have a wide range of therapeutic effects and
can act as immune-modulatory, anticarcinogenic, antiviral,
antioxidant, and anti-inflammatory agents [16, 20]. The con-
centration and efficacy of the bioactive compounds are varied
and depend on the type of mushroom, substrate applied,
cultivation and fruiting conditions, stage of development,
age of the fresh mushroom, storage conditions, and pro-
cessing and cooking procedures [41]. Many of the bioactive
compounds found in mushrooms exhibit significant anti-
inflammatory properties. Table 1 lists most of the well-known
mushroom species reported in the literature as possessing
anti-inflammatory activities, along with their bioactive com-
pounds and the solvent applied for extraction.
3.1. Polysaccharides. Polysaccharides represent the major
class of bioactive compounds found in mushrooms, and have
been reported in most of the edible types. Bernardshaw et
al. [49] investigated the effect of an aqueous polysaccharide
extract of Agaricus blazeiMurill on the stimulation of proin-
flammatory cytokine production in human monocytes and
human vein endothelial cells in vitro. They reported that A.
blazei extract is rich in 𝛽(1,3)-, 𝛽(1,4)-, and 𝛽(1,6)-D-glucans
(Figure 1) and induces the release of proinflammatory cyto-
kines (IL-1𝛽, IL-6, IL-8) and 𝛼TNF. Another research has also
reported that A. blazei extract enhances local and systemic
inflammation, upregulates proinflammatory molecules, and
enhances leukocyte homing to atherosclerosis sites without
affecting the lipoprotein profile [50].
Contrary to these results, reports have recently appeared
indicating that polysaccharides from A. blazei exert anti-
inflammatory activities. Song et al. [51] investigated the anti-
inflammatory and antiallergic effects of the chloroform-
soluble extract of A. blazei in mouse bone-marrow-derived
mast cells (BMMCs). They found that the extract inhibited
the production of IL-6 in phorbol myristate acetate (PMA)
plus calcium ionophore A23187-stimulated BMMCs and
downregulated the phosphorylation of the serine/threonine
kinase AKT. Furthermore, the extract inhibited the degran-
ulation of 𝛽-hexosaminidase, as well as the production of
prostaglandin D(2) and leukotriene C(4). They concluded
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Table 1: Anti-inflammatory compounds of mushrooms.
Mushroom species Biomaterial
source
Extracting
solvent Bioactive compound
References
Agaricus blazei WM 1 Polysaccharides [51]
A. bisporus WM 3
Pyrogallol, hydroxybenzoic acid derivatives,
flavonoids.
[91]
FB 4 Polysaccharide (fucogalactan) [65]
A. subrufescens WM 2 Polysaccharide (proteoglucan) [55]
Agrocybe aegerita FB 3 Fatty acids [88]
A. cylindracea FB 2 Agrocybin [98]
Albatrellus caeruleoporus FB 3 Phenolic compound (Grifolinones A, B) [93, 94]
Amanita muscaria FB 2, 3, 4 Crude extract [99]
Boletus edulis WM 3 polysaccharides, [91]
Cantharellus cibarius WM 3 Pyrogallol, flavonoids, polysaccharides [91]
C. tubaeformis WM 2 Polysaccharides [74]
Cordyceps militaris SC/FB 4 Crude extract [100]
C. pruinosa FB 3 Crude extract [101]
Caripia montagnei FB 3 Polysaccharides (Glucans) [63]
Cyathus africanus SC 5 Diterpenoid [76]
C. hookeri SC 5 Diterpenoid [77]
Daldinia childiae FB N.M. Benzophenones (daldinals A-C) [92]
Elaphomyces granulatus FB 4 Syringaldehyde, syringic acid [19, 96]
Flammulina velutipes WM 4 Polysaccharides [72]
Fomitopsis pinicola SC 4 Polysaccharides [102]
Grifola frondosa SC 5, 6 Agaricoglycerides [97]
SC 3, 5, Ergosterol(1-oleoyl-2-linoleoyl-3-palmitoylglycerol)
[103]
Ganoderma lucidum FB 4 Triterpene [78]
FB 4 Lucidenic acid, ganoderic acid [81]
Geastrum saccatum FB 4 Polysaccharides (𝛽-glucans) [104]
FB 2, 4, 5 Crude extract [82]
Inonotus obliquus FB 8, 5
Ergosterols, lanosterol, inotodiol, trametenolic
acid
[84]
FB 3 Crude extract [83]
FB 4 Crude extract [105]
Lactarius deliciosus WM 3 Pyrogallol, flavonoids [91]
L. rufus FB 2, 4 Polysaccharides: (1→ 3), (1→ 6)-𝛽-D-glucans [64]
Lentinus edodes FB 2 Heterogalactan (fucomannogalactan) with mainchain of (1→ 6)-linked 𝛼-D-glactopyranosyl unit
[66]
L. polychrous SC 4 Crude extract [67]
Lyophyllum decastes FB 3 Polysaccharides: (1–3) and (1–6) 𝛽-D-glucans [106]
Phellinus linteus FB 9 Polysaccharides (proteoglycan) [69]
FB 4, 7, 9 Crude extract [107]
Pholiota nameko WM 4, 6, 10 Polysaccharides [71]
Pleurotus pulmonarius FB N.M. Polysaccharides (1→ 3), (1→ 6)-linked 𝛽-glucan [60]
FB 2, 4 Polysaccharides (Glucan) [57]
Poria cocos SC 4 Polysaccharides [108]
Termitomyces albuminosus SC/FB 4 Crude polysaccharide extract [68]
WM, whole mushroom; SC, submerged culture; FB, fruiting bodies.
Solvent: N.M., not mentioned; 1, chloroform; 2, water; 3, methanol; 4, ethanol; 5, ethyl acetate; 6, acetone; 7, n-hexane; 8, petroleum ether; 9, n-butanol; 10,
acetyl ether.
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Figure 1: Molecular structure of 𝛽-(1→ 3)-D-glucans (a) and 𝛼-(1→ 3)-D-glucans (b).
that their A. blazei extract has anti-inflammatory and anti-
allergic activities, which are regulated by affecting IL-6,
prostaglandin D(2), leukotriene C(4), and the phosphoryla-
tion of the serine/threonine kinase AKT.
In 2009, Johnson et al. [52] reported a phase I clinical trial
in which 15 healthy individuals were given a daily oral dose of
60mL of aqueous extract of AndoSan (a mushroom extract
mixture containing 82% A. blazei mycelium, 15% Hericium
erinaceum, and 3% Grifola frondosa) for 12 days.Their results
showed a significant in vivo reduction in the levels of IL-
1𝛽, TNF-𝛼, IL-6, IL-2, and IL-7 proinflammatory cytokines
and unaltered levels of the remaining 12 cytokines. They
concluded that the applied extract has an anti-inflammatory
effect [52]. In 2011, they conducted another clinical pilot study
in order to prove these results. They treated 21 hospitalized
patients with inflammatory bowel diseases, ulcerative colitis,
and Crohn’s disease with the same AndoSan treatment dose
(60mL/d for 12 days). They noticed a significant decrease in
plasma levels of the proinflammatory cytokines as well as
a decrease in calprotectin, an inflammatory marker, in the
faeces of ulcerative colitis patients [53].
Ellertsen and Hetland [54] attributed the apparently con-
tradictory findings reported above to the fact that the effect
of A. blazei extract differs according to the molecular size of
active compound and the type of study performed (i.e., in
vitro or in vivo). They found that in vitro cell culture studies
showed increased proinflammatory cytokines, while in vivo
human studies showed an anti-inflammatory response. They
suggested that cells in vitro are affected by all substances
present in the extract, including high molecular weight 𝛽-
glucans. On the other hand, in human in vivo studies, it is
mainly the smaller substances which are absorbed into the
digestive tract to become active in blood. Additionally, they
found that the regulatory genes of the leukocytes affected by
the A. blazei extract differ in their expression in vitro and
in vivo. Genes regulating proinflammatory cytokines were
strongly induced in vitro, probably by the high molecular
weight 𝛽-glucans, whereas, in vivo, genes controlling anti-
inflammatory reactions were upregulated, due to low molec-
ular weight glucans. This hypothesis was supported by the
mixed composition of the AndoSan extract, which contained
both high and low molecular weight polysaccharides.
Other studies have reported that the protein-bound
polysaccharides in the aqueous extract of A. subrufescens
enhance defencemechanisms against invasive organisms and
bacterial infection and reduce the plaque formation of viruses
in cell cultures [49, 55, 56].
Additionally, glucans ((1→ 3)-𝛽-D-glucopyranosyl) from
Pleurotus pulmonarius have been reported to exhibit anti-
inflammatory properties [57–59]. These studies demon-
strated that the fruiting body, ormycelial extract, of the edible
mushroom markedly attenuated or suppressed symptoms
associated with dextran sulphate sodium-induced acute coli-
tis in mice. They also reported that, in an in vitro study, these
glucans inhibited TNF-𝛼-dependent activation of NF-𝜅B in
human intestinal cells [57]. Furthermore, 𝛽-glucans from
P. pulmonarius exhibited an anti-inflammatory response in
a model of acute colitis in rats, and when those from P.
ostreatus were tested, they inhibited leukocyte migration to
acetic acid-injured tissues [60, 61]. Recently, Jedinak et al.
[62] showed that oyster mushroom concentrate (OMC) con-
taining 𝛼- and 𝛽-glucans suppressed LPS-induced dependent
activation of TNF-𝛼, IL-6, and IL-12 in RAW 264.7 murine
macrophage cells, as well as inhibiting LPS-induced produc-
tion of prostaglandin E2 (PGE2) and nitric oxide (NO). This
was mainly attributed to the downregulation of COX-2 and
iNOS expression, respectively. They also reported that OMC
significantly suppressed LPS-induced production of TNF-
𝛼 in mice and concanavalin A-stimulated proliferation and
secretion of INF-𝛾, IL-2, and IL-6 in mouse splenocytes [62].
The methanolic extract of Caripia montagnei (mainly
polysaccharides of the glucan type) has also been shown to
exert anti-inflammatory effects on male Swiss mice and male
Wistar rats. The glucans significantly reduced the inflamma-
tory infiltrate produced by thioglycolate-mediated peritonitis
by about 75%. Additionally, a significant reduction in the
nitric oxide levelswas observed in the exudates [63]. Ruthes et
al. [64], meanwhile, investigated water and ethanolic extracts
of (1→ 3), (1→ 6)-𝛽-D-glucans from the fruiting bodies of
Lactarius rufus for their anti-inflammatory effects in both
male and female Swiss mice. They found that soluble glucans
inhibit inflammatory pain caused by formalin in comparison
to the insoluble glucans, concluding that solubility and/or
branching degree can alter the activity of 𝛽-glucans.
Furthermore, the aqueous extract of fucogalactan from
Agaricus bisporus exhibited anti-inflammatory response in
male Swiss mice [65]. It inhibited the neurogenic and inflam-
matory phases of formalin-induced licking, which they attrib-
uted to the decreased iNOS and COX-2 expression. Addition-
ally, heterogalactans isolated by cold aqueous extraction from
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Figure 2: Examples of some terpenoid bioactive compounds isolated from edible mushrooms.
Lentinus edodes have shown anti-inflammatory activities in
male Swiss mice [66]. The active fraction was made of
fucomannogalactan with a main chain of (1→ 6)-linked 𝛼-
D-galactopyranosyl units, partially substituted at O-2 with
single-unit 𝛽-D-Manp or 𝛼-L-Fucp side chains. The polysac-
charide produced a marked effect against acetic acid induced
visceral nociception and inhibited the peritoneal capillary
permeability and leukocyte infiltration.
Mushroom polysaccharides with anti-inflammatory prop-
erties have been also reported in crude extracts of Lentinus
polychrous, Termitomyces albuminosus, and Phellinus linteus.
In L. polychrous, they inhibited NO and proinflammatory
productions by downregulating the gene expressions of pro-
inflammatory mediators, thereby decreasing paw oedema in
rats [67]. In T. albuminosus, they decreased the acetic acid
induced writhing response and the licking time in the late
phase in the formalin test in male ICR mice [68]. Addition-
ally, mouse ear swelling was inhibited by 61.8, 79.0, and 81.6%
when the animals were treated with the dry matter of the cul-
ture broth (1000mg/kg), crude saponin extract (200mg/kg),
or crude polysaccharide extract (200mg/kg), respectively.
In another study, polysaccharides of P. linteus inhibited the
mouse ear oedema induced by croton oil, reduced the amount
of writhing induced by acetic acid in mice [69], induced
heme oxygenase-1 (HO-1) of the RAW 264.7 macrophages,
and suppressed iNOS and the subsequent production of
nitric oxide by downregulation of iNOS promoter activity in
lipopolysaccharide-stimulated macrophages [70].
The polysaccharides of Pholiota nameko have been
reported to inhibit topical oedema in mouse ears and sig-
nificantly suppress the development of egg albumin-, carra-
geenan-, and formaldehyde-induced paw oedema in the ani-
mals, and, significantly, did not produce any gastric lesions in
rats [71].Thepolysaccharides of the golden needlemushroom
(Flammulina velutipes) are composed of three monosaccha-
rides (glucose, mannose, and xylose) in a molar ratio of
3.5 : 0.8 : 1.4 and have been found to have anti-inflammatory
activities and significantly decreased CD4+ CD8+, ICAM-1,
andMPO in both the serum and colon of normal and burned
rats [72]. Tibetan mushroom polysaccharides also exhibited
an anti-inflammatory activity by significantly inhibiting the
formation of granuloma tissue by about 43% as well as
significantly decreasing rat paw oedema induced by car-
rageenan [73]. Polysaccharides extracted from Cantharellus
tubaeformis [74] and Lactarius flavidulus [75] have also been
reported to exhibit anti-inflammatory properties. Table 2
summarizes some of the biological studies carried out with
different compounds having anti-inflammatory activities iso-
lated from mushrooms.
3.2. Terpenoids. Terpenes are the largest group of anti-inflam-
matory compounds in mushrooms and have been isolated
from a range of different strains (Figure 2). Han et al. [76] iso-
lated five novel cyathane diterpenes, identified as cyathins D-
H (1–5), in addition to three well known diterpenes, namely,
neosarcodonin, cyathatriol, and 11-O-acetylcyathatriol from
the ethylacetate extract of Cyathus africans. They found that
cyathins D-H 3 and 5, as well as neosarcodonin and 11-O-
acetylcyathatriol, showed potent inhibition activity against
NO production in lipopolysaccharide-mouse monocyte-
activated macrophage RAW 264.7, with IC
50
values of 2.75,
1.47, 12.0, and 10.73 𝜇M, respectively. Xu et al. [77] isolated
three bioactive diterpenes from the ethylactetate extract
of C. hookeri Berk, namely, cyathin, (12R)-11a,14a-epoxy-
13a,14b,15-trihydroxycyath-3-ene, and erinacine I. They also
found that each of their three isolated diterpenes showed
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Table 2: Examples of biological studies performed with anti-inflammatory compounds from mushrooms.
Bioactive compound/
mushroom species Assay model Results/mechanism of action References
Polysaccharides
Agaricus blazei
(i) Mouse bone marrow-derived mast
cells (BMMCs) stimulated with PMA
+ A23187
(i) Inhibition of IL-6 production,
downregulation of phosphorylation of Akt,
inhibition of 𝛽-hexosaminidase degranulation,
inhibition of prostaglandin D(2), and
leukotriene C(4) production.
[51]
(i) Male Swiss mice (acetic acid
induced inflammation)
(i) Dose-dependent anti-inflammatory
response, inhibition of leukocyte migration
(82%), IC50 of 1.19 (0.74–1.92) mg/kg, 3mg/kg
i.p. glucan injection reduced 85% of writhes
[60]
Pleurotus pulmonarius
(ii) Mice (3.5% dextran sulfate sodium,
DSS in drinking water for 14 days, with
20mg fruiting body or mycelia
extract/mouse/day)
(ii) Fruiting body and mycelia extracts
suppressed inflammatory reactions in vivo in
DSS induced colonic inflammation by
downregulating TNF-𝛼 secretion and
inhibiting NF-𝜅B activation
[57, 58]
(iii) Acetic acid induced colitis in rats
(2% pleuran, or 0.44% hydrogel for 4
weeks)
(iii) Reduction in macroscopic damage score
by 51 and 67% for pleuran diet and hydrogel,
respectively; reduction in the activity of
myeloperoxidase and neutrophil infiltration
[61]
(iv) Murine macrophage RAW264.7
cells, female Balb/C mice
(iv) Suppression of LPS-induced dependent
activation of TNF-𝛼, IL-6, and IL-12, inhibition
of LPS-induced production of PGE2 and NO.
Suppression of LPS-induced production of
TNF-𝛼 in mice and concanavalin A-stimulated
proliferation and secretion of INF-𝛾, IL-2, and
IL-6 in mouse splenocytes
[62]
Caripia montagnei (i) Male Swiss mice treated with 10, 30,and 50mg/kg with mushroom glucan
(i) 50mg/kg glucan reduced inflammatory
infiltrate produced by thioglycolate-induced
peritonitis by 75.5%, reduced NO level, IL-1ra,
IL-10, and IFN-𝛾
[63]
Lactarius rufus
(i) Swiss mice, formalin-induced
nociception, 30mg/kg i.p. of fruiting
body extract (soluble, insoluble, and
modified)
(i) Inhibition of neurogenic pain by 36, 47, and
58% for soluble, insoluble, and modified
glucans, respectively [64]
A. bisporus (i) Male Swiss mice, formalin-inducedlicking
(i) Inhibition of neurogenic and inflammatory
phases, antinociceptive effect with IC50 of 36.0
(25.8–50.3mg/kg)
(ii) Decreased iNOS and COX2
[65]
Lentinus edodes
(i) Male Swiss mice, acetic acid
induced inflammation, 3–100mg/kg
i.p. fruiting body concentrate
(i) Inhibition of induced nociception with IC50
of 13.8 (7.8–23.5) mg/kg, 97% inhibition at
100mg/kg
(ii) Inhibition of peritoneal capillary
permeability and leukocyte infiltration (76%
inhibition), IC50 13.9, 8.2–23.7, and 100%
inhibition, IC50 6.5, 1.5–28.2mg/kg,
respectively
[66]
L. polychrous (i) Carrageenan-induced paw edemain male Sprague-Dawley rats, murine
macrophage RAW 264.7 cells
(i) Dose-dependent inhibition of NO,
intracellular O
2
− production
(ii) Decreased expression of iNOS, IL-1𝛽, IL-6,
TNF-𝛼, and COX-2
[67]
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Table 2: Continued.
Bioactive compound/
mushroom species Assay model Results/mechanism of action
References
Termitomyces albuminosus
(i) Acetic acid induced writhing in
male ICR mice, formalin test, xylene,
and carrageenan induced ear edema
(i) Inhibition of ear swelling by 61.8, 79.0, and
81.6% for treatment with dry matter of the
culture broth (1000mg/kg), crude saponin
extract (200mg/kg), or crude polysaccharide
extract (200mg/kg), respectively
[68]
Phellinus linteus
(i) Croton oil induced ear edema and
acetic acid induced writhing in male
ICR mice
(i) Extract treatment with 1mg/ear gave 45 and
41.5% inhibition in ear plug weight and
thickness, respectively, oral administration of
extract (100–400mg/kg) inhibited writhing
number (35.9–68.9%)
[69]
Pholiota nameko
(i) Xylene induced ear edema, adult
Swiss mice and Sprague-Dawley rats,
formaldehyde, egg albumin, and
carrageenan induced paw edema in
rats and mice
(i) Extract (5mg/ear) inhibited ear edema,
suppression of egg albumin, carrageenan and
formaldehyde-induced paw edema at
100–400mg/kg i.p., 10.96–43.75% inhibition of
granuloma tissue growth, no production of
gastric lesions in rats
[71]
Flammulina velutipes (i) Male Wistar rats, fed100–300mg/kg mushroom for 30 days
(i) Decreased levels of CD4+ CD8+, MPO, and
ICAM-1, with increased level in IL-10 in serum
[72]
Terpenoids
Cyathus africanus (i) Mouse monocyte-macrophageRAW 264.7 cells, NO assay
(i) Cyathins D-H 3 and 5, neosarcodonin, and
11-O-acetylcyatha-triol inhibited NO
production with an IC50 value of 2.75, 1.47, 12.0,
and 10.73 𝜇M, respectively
[76]
C. hookeri (i) Mouse monocyte-macrophageRAW 264.7 cells, NO assay
(i) Inhibition of NO production with an IC50 of
15.5, 52.3, and 16.8 𝜇M, respectively. [77]
Ganoderma lucidum
(i) LPS-stimulated murine macrophage
RAW 264.7 cells, NO assay
(i) Inhibition of TNF-𝛼, IL-6, NO, and PGE2,
downregulation of iNOS and COX-2,
inhibition of NF-𝜅B, decreased NF-𝜅B-DNA
binding activity, and suppression of p65
phosphorylation
[78]
(ii) Acetic acid induced ear edema in
female ICR and SENCAR mice
(ii) Significant inhibition of inflammation
(1 𝜇g/ear) in mice with IC50 values between
0.07 and 0.39mg/ear, with inhibition ratio
ranging from 58 to 97%
[81]
(i) Reduced nitrate levels by an average of 50%,
dose-dependent inhibition of IL-1𝛽, IL-6, and
TNF𝛼
[82]
Inonotus obliquus (i) Murine macrophage RAW 164.7
cells
(ii) Trametenolic acid, ergosterol peroxide,
3𝛽-hydroxy-8,24-dien-21-al, ergosterol and
inotodiol inhibited NO production, and NF-𝜅B
luciferase activity, with an inhibition
percentage of 50.04, 36.88, 20.36, 6.00, and
3.13%, respectively
[84]
(iii) Methanolic extract inhibited production of
NO, prostaglandin E2, and TNF-𝛼, inhibition
of mRNA expression of iNOS and COX-2
[83]
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Table 2: Continued.
Bioactive compound/
mushroom species Assay model Results/mechanism of action References
Peptides
Cordyceps sinensis (i) Acetic acid induced inflammationin mice
(i) Decreased level of TNF-𝛼, IL-1𝛽,
dose-dependent inhibition of abdominal
constrictions
[86]
Phenolics
Lactarius deliciosus
(i) LPS-stimulated RAW 364.7
macrophage cells, nitrite, and cytokine
assays
(i) 0.5mg/mL mushroom extract inhibited NO
production and expression of iNOS, IL-1𝛽, and
IL6 mRNAs [91]
Daldinia childiae (i) LPS-stimulated RAW 264.7macrophage cells
(i) Daldinals suppressed NO production with
IC50 values ranging between 4.6 and 15.2 𝜇M
and inhibited iNOS mRNA synthesis [72]
Albatrellus caeruleoporus (i) LPS-stimulated mouse macrophageRAW 264.7 cells
(i) Grifolins inhibited NO production with
IC50 values ranging between 22.9 and 29 𝜇M
[94]
Syringaldehyde and syringic acid
Elaphomyces granulates (i) Mouse macrophage RAW 264.7cells
(i) Crude ethanolic extract (50 𝜇g/mL)
inhibited COX-2 activity by 68%, purified
syringaldehyde, and syringic acid inhibited
COX-2 activity in a dose-dependent manner,
with an IC50 of 3.5 and 0.4 𝜇g/mL, respectively
[96]
Agaricoglycerides
Grifola frondosa
(i) Acetic acid- and formalin-induced
inflammation in Wister rats, treatment
with orally fed extracts
(100–500mg/kg/day)
(i) 500mg/kg/day inhibited induced
upregulation of NF-𝜅B and the production of
IL-1𝛽, TNF-𝛼, ICAM-1, COX-2, and iNOS,
suppressed acetic acid induced abdominal
constrictions and formalin-induced
spontaneous nociceptive behavior
[97]
potent anti-inflammatory activities, inhibiting NO produc-
tion in mouse monocyte-macrophages RAW 264.7, with an
IC
50
of 15.5, 52.3, and 16.8 𝜇M, respectively.
Another class of terpenoids (triterpenes) have also been
shown to exhibit high anti-inflammatory properties [78].
The authors of this study evaluated the anti-inflammatory
effects of triterpene extract of Ganoderma lucidum in
lipopolysaccharide- (LPS-) stimulated macrophages. They
reported that the triterpene extract significantly suppressed
the secretion of inflammatory cytokine tumour necrosis
factor-𝛼 (TNF-𝛼) and interleukin-6 (IL-6), as well as the
inflammatorymediators nitric oxide (NO) and prostaglandin
E2 (PGE2), from LPS-stimulated murine RAW 264.7 cells.
Additionally, the LPS-dependent expression of inducible
nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-
2) in RAW 264.7 cells were downregulated. The anti-inflam-
matory effects of the triterpene extract have been attributed
to the inhibition of transcription factor NF-𝜅B, as observed
in the decreased NF-𝜅B-DNA binding activity, as well as
the suppression of p65 phosphorylation in the treated LPS-
stimulated macrophages. Additionally, the extract inhibited
LPS-dependent AP-1-DNA binding activity and downregu-
lated the expression of AP-1 subunit c-Jun. Furthermore, the
activity of MAP kinases has been suppressed, as observed
by the downregulation of LPS-induced phosphorylation of
ERK1/2 and JNK.
Furthermore, different lanostane-type triterpenic acids
with potent anti-inflammatory properties have been isolated
fromG. lucidum [79, 80]. Akihisa et al. [81] reported that nine
lucidenic acids and four ganoderic acids (Figure 3), isolated
from the fruiting bodies ofG. lucidum, significantly inhibited
12-O-tetradecanoylphorbol-13-acetate induced inflammation
(1 𝜇g/ear) in mice, with IC
50
values between 0.07 and
0.39mg/ear.
Different sterols (Figure 4) with potent anti-inflammatory
activities have been also isolated and purified from the edible
mushroom Inonotus obliquus. These significantly inhibited
the levels of IL-1𝛽, IL-6, and TNF𝛼 in a dose-dependentman-
ner in murine macrophage RAW 164.7 cells [82]. Addition-
ally, Park et al. [83] found that the methanolic extract of I.
obliquus significantly inhibited NO production, prosta-
glandin E
2
, and TNF-𝛼 in LPS-stimulated RAW 264.7
macrophages. Ma et al. [84] isolated and identified six known
triterpenes from the sclerotia of I. obliquus. They reported
that trametenolic acid, ergosterol peroxide, 3𝛽-hydroxy-8,24-
dien-21-al, ergosterol, and inotodiol inhibitedNOproduction
and NF-𝜅B luciferase activity in macrophage RAW 264.7
cells, with an inhibition percentage of 50.04, 36.88, 20.36,
6.00, and 3.13%, respectively.
3.3. Peptides. In addition to the previous bioactive com-
pounds, anti-inflammatory peptides of different molecular
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Ganoderic acids
COOH
H
Ganodermanotriol
H
O
OH
OH
HO
R1 R2
R3 R6
R4
R5
A: R1 = R3 = R6 = O, R2 = R5 = 𝛽-OH, R4 = H
B: R1 = R3 = R5 = R6 = O, R2 = 𝛽-OH, R4 = H
D: R1 = R3 = R5 = R6 = O, R2 = R4 = 𝛽-OH,
F: R1 = R2 = R3 = R5 = R6 = O, R4 = 𝛽-OH,
G: R1 = R2 = R4 = 𝛽-OH, R3 = R5 = R6 = O,
H: R1 = 𝛽-OH, R2 = R3 = R5 = R6 = O, R4 = 𝛽-OAC
Z: R1 = 𝛽-OH, R2 = R3 = R4 = R5 = R6 = H
Figure 3: Structures of different ganoderic acids and derivative isolated from G. lucidum.
HO
Lanosterol
HO
Ergosterol
HO HO
OH
Inotodiol
HOOC
HO
Trametenolic acidErgosterol peroxide
HO
O
O
HOH2C
3-𝛽-Hydroxy-8,24-dien-21-al
Figure 4: Structures of different sterol compounds isolated from I. obliquus.
weights have been isolated from mushrooms. Cordymin, a
low molecular weight peptide (10,906Da), has been puri-
fied from the medicinal mushroom Cordyceps sinensis [85,
86] and from C. militaris [87]. This peptide significantly
inhibited the infiltration of polymorphonuclear cells and IR-
induced upregulation of C3 protein produced in the brain,
interleukin-1𝛽, and tumour necrosis factor-𝛼, which had a
neuroprotective effect on the ischemic brain, due to the
inhibition of inflammation. Agrocybin represents another
peptide isolated from the edible mushroom Agrocybe cylin-
dracea. Agrocybin exhibited antifungal activity againstMyco-
sphaerella arachidicola, with an IC
50
value of 125 𝜇Mat differ-
ent temperatures up to 80∘C [88].
3.4. Phenolics. Many edible mushrooms have been found to
exhibit anti-inflammatory properties due to the presence of
some phenolic compounds (Figure 5). For example, the com-
mon phenolic molecule pyrogallol has been extracted from
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C OH
OHC
O
H3CO
OCH3
CH3 OCH3
(a)
HO
OH
OH
(b)
Figure 5: Chemical structures of (a) daldinal and (b) pyrogallol.
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Figure 6: Grifolin and neogrifolins isolated from Albatrellusmushrooms.
Agaricus bisporus, Cantharellus cibarius, and Lactarius deli-
ciosus [89, 90]. Pyrogallol inhibited NO production and
iNOS, IL-1𝛽, and IL6 mRNAs expression in response to LPS-
stimulated RAW 364.7 macrophages [91]. Additionally, dald-
inals have been purified fromDaldinia childiae.They strongly
suppressed the LPS-induced production ofNO inRAW264.7
cells, with IC
50
values ranging between 4.6 and 15.2 𝜇M
depending on the derivative [92]. This effect was attributed
to the inhibition of iNOS mRNA synthesis.
Grifolin and grifolin derivatives (Figure 6) represent
another class of farnesyl phenolic compounds which have
been isolated from the edible mushroom Albatrellus ovinus
and which exhibit anti-inflammatory properties [93]. Gri-
folins showed significant inhibition of NO production stim-
ulated by LPS in RAW 264.7 cells, with IC
50
values ranging
between 22.9 and 29 𝜇M [94], as well as inhibiting histamine
release from rat peritoneal mast cells [95].
OH
CHO
Syringaldehyde Syringic acid
OH
COOH
H3CO H3COOCH3 OCH3
Figure 7: Structure of anti-inflammatory compounds isolated from
edible truffles.
3.5. Miscellaneous. The ectomycorrhizal edible truffle Elaph-
omyces granulatus has been evaluated for its anti-inflam-
matory effects. The 95% ethanolic extract of the fruiting
bodies contained two active aromatic compounds with anti-
inflammatory and antioxidant activities, namely, syringalde-
hyde and syringic acid (Figure 7). The anti-inflammatory
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properties of these two low molecular weight organic com-
pounds were proven by their inhibition of the mediator
cyclooxygenase-2 (COX-2) enzyme in mouse macrophage
(RAW 264.7). The crude ethanolic extract caused about
68% inhibition of the enzyme activity at a concentration of
50𝜇g/mL. The inhibitory effect of the purified syringalde-
hyde and syringic acid on COX-2 activity showed a dose-
dependent effect, with an IC
50
of 3.5 and 0.4 𝜇g/mL, respec-
tively, [19, 96].
Agaricoglycerides represent a new class of fungal sec-
ondary metabolites that constitute esters of chlorinated 4-
hydroxy benzoic acid and glycerol and are produced in the
culture of different edible mushrooms such as Grifola fron-
dosa and Agaricus macrosporus. They also exhibited signif-
icant anti-inflammatory activity. The agaricoglycerides iso-
lated from Grifola frondosa (AGF) showed potent anti-
inflammatory activity since they were able to reduce the level
of many mediators, such as IL-1𝛽, NF-𝜅B, ICAM-1, COX-
2, and iNOS in animal models [97]. This study showed that
an oral dose of 500mg/kg/day of the ethanolic extract of an
agaricoglyceride mixture showed strong anti-inflammatory
activity in a Wister rat animal model.
4. Future Perspectives
This review has demonstrated the importance of mushrooms
as potential biofactories for the production of natural anti-
inflammatory metabolites of highly diversified chemical
structure.The bioactivities of these compounds are exhibited
through the downregulation of different types of inflamma-
tory mediators. In addition to the high potential application
of anti-inflammatory metabolites from mushrooms in forms
of unpurified extract and extra pure compounds in medical
applications, they can also be used in cosmeceutical products
as safe and natural active ingredients without undesired
side effects. However, the future medical application of anti-
inflammatory compounds isolated from mushrooms faces
five main challenges. Firstly, most of the studied mushrooms
are not cultivable in greenhouses, and thus their availability is
both seasonal and highly affected by changes in the weather.
Secondly, the contents of the bioactive ingredients vary
widely between samples, dependent on the collection time
and procedure, the season, and the environment. Thirdly,
mushroom cultivation in greenhouses is an open system
and is not run according to the current Good Manufac-
turing Practice (cGMP) requirements for the production of
bioactive medicinal compounds. Therefore, more research
should be done on the development of mushroom cultivation
processes in submerged cultures under fully sterile conditions
so as to produce bioactive metabolites for pharmaceutical
applications. Fourthly, inmost of the studies conducted so far,
the anti-inflammatory activities of mushrooms were demon-
strated using crude mushroom extracts or solvent extracts
of different metabolites in a mixed form. It is necessary,
therefore, to isolate and identify the active metabolites for a
better understanding of the anti-inflammatory properties of
each particular compound and the possible side effects, if any.
This step is necessary to upgrade the crude extract from a
nutraceutical to pharmaceutical market after proper product
formulation and clinical trials to determine the proper dose
and claims. Fifthly, there is a lack of validated standard
testing protocols to guarantee the quality and the efficacy of
mushroom products for pharmaceutical applications. Over-
all, therefore, more research is required to overcome the
challenges mentioned above before macrofungi can be fully
accepted as one of the major biofactories for the production
of anti-inflammatory medicine.
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